![Steffen Walter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steffen Walter
Operationeel Directeur bij
IMMATICS N.V.
Vermogen: 115 100 $ op 31-05-2026
Profiel
Steffen Walter is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Scientific Officer since 2015.
Dr. Walter currently holds the position of Chief Operations Officer at Immatics Biotechnologies GmbH since 2023, with the job starting in 2005 and ongoing.
Dr. Walter also holds the position of Chief Operations Officer at Immatics NV since 2023, with the job starting in 2020 and ongoing.
Dr. Walter completed a doctorate degree at Eberhard Karls Universität Tübingen.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMMATICS N.V. 0,01% | 18-03-2026 | 10.000 ( 0,01% ) | 115 100 $ | 31-05-2026 |
Actieve functies van Steffen Walter
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMATICS N.V. | Operationeel Directeur | 21-03-2023 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Oprichter | 01-01-2015 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Operationeel Directeur | 21-03-2023 |
Opleiding van Steffen Walter
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
19
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
 Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
